Trial Profile
A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors MedImmune
- 28 Dec 2020 Data from 7 studies (NCT00757042, NCT00972179, NCT01405963, NCT01913028, NCT02512900, NCT02525094 & NCT02054130) was used to develop a population PK model to guide tezepelumab dose selection for phase III trials in patients with severe asthma, published in the Journal of Clinical Pharmacology.
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 08 Jul 2016 Status changed from active, no longer recruiting to completed.